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Abstract
The hRAD54 gene is a key member of the RAD52 epistasis group involved in repair of double-strand breaks (DSB)
by homologous recombination (HR). Thus, alterations of the normal function of these genes could generate genetic
instability, shifting the normal process of the cell cycle, leading the cells to develop into cancer. In this work we ana-
lyzed exon 18 of the hRAD54 gene, which has been previously reported by our group to carry a silent polymorphism,
2290 C/T (Ala730Ala), associated to meningiomas. We performed a PCR-SSCP method to detect the polymorphism
in 239 samples including leukemia and normal control population. The results revealed that the 2290 C/T polymor-
phism has frequencies of 0.1 for the leukemia and 0.1 for the control group. These frequencies show no statistical dif-
ferences. Additionally, we dissected the leukemia group in chronic myelogenous leukemia (CML) and acute
lymphoblastic leukemia (ALL) to evaluate the polymorphism. The frequencies found in these subgroups were 0.14
for CML and 0.05 for ALL. We found statistically significant differences between CML patients and the control group
(p < 0.05) but we did not find significant differences between ALL and the control group (p > 0.05). These results sug-
gest a possible link between the 2290 C/T polymorphism of the hRAD54 gene and CML.
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DNA repair is a major feature for maintenance of ge-
nome stability and integrity in living cells. DNA dou-
ble-strand breaks (DSB) are lesions that threaten the integ-
rity of the genome. If not properly processed, DSB can lead
to cell cycle arrest or illegitimate DNA rearrangements
such as translocations, inversions, or deletions, which con-
tribute to cell dysfunction, cell death, or carcinogenesis
(Wesoly et al., 2006).
It is known that the chromosomal aberrations that ac-
tivate oncogenes and trigger the carcinogenic process al-
ways involve double-stranded DNA exchanges. This phe-
nomenonmaybeproducedbyDSB(Lengaueretal.,1998).
One major repair pathway in eukaryotic cells in order to
eliminate deleterious effects is homologous recombination
(HR) (Kooistra et al., 1997). HR is generally a precise way
of resolving DSB and successful chromosome segregation
during meiosis (Mazina and Mazin, 2008). Moreover, dys-
regulation of HR may lead to aberrant genetic rearrange-
ments and genomic instability, resulting in various muta-
tions (Park et al., 2008).
ThehRAD54geneplaysanimportantroleinhomolo-
gous recombination and DNA double-strand break repair.
Rad54 belongs to the Snf2/Swi2 protein family. It pos-
sessesarobustDNA-dependentATPaseactivity,usesATP
hydrolysis to supercoil DNA and cooperates with the
Rad51 recombinase in DNA joint formation (Smirnova et
al., 2004; Rossi and Mazin, 2008). This gene has been
mapped at chromosome 1p32 by fluorescent in situ hybrid-
ization (FISH) (Kanaar et al., 1996). The (1p32) region has
been found to be a site of high rates of loss of hetero-
zygosity, and concentrates six single nucleotide polymor-
phisms (SNP) that have been associated with genetic
instability in meningiomas (Leone et al., 1999, 2003).
hRAD54 also has been proposed as an oncosupressor in
breast cancer and several point mutations in conserved re-
gions of the hRAD54 gene have been found in primary tu-
mors such as colonic adenocarcinoma, non-Hodgkin
lymphoma and breast carcinoma (Smirnova et al., 2004).
Moreover, the 1p32 region is a common partner for bal-
anced translocation in hematological and lymphoid malig-
Genetics and Molecular Biology, 33, 4, 646-649 (2010)
Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to: César Paz-y-Miño. Instituto de Investi-
gaciones Biomédicas, Facultad de Ciencias de la Salud, Uni-
versidad de las Américas, Av. de los Granados E12-41 y Colimes,
Quito, Ecuador. E-mail: cpazymino@udla.edu.ec.
Short Communicationnancies, e.g. t(1;14) (p32;q11) and t(1;3) (p32;q27) in
leukemia and lymphoma, respectively (Cotter, 1998;
Rubnitz and Pui, 1998).
In this work, we analyzed the status of the 2290 C/T
silent polymorphism in exon 18 of the hRAD54 gene in the
Ecuadorian population. It is reported that the polymor-
phismisassociatedwithmeningiomas(Leoneetal.,2003),
suggesting that this alteration could be involved in
tumorigenesis. Therefore, the objective of this study was to
relate the T allele distribution to leukemia development.
Leukemia is a malignant disease which is character-
ized by the presence of carcinogen cells in bone marrow
and blood. According to the cancer cell type involved, this
disease is classified as lymphocytic and myelogenous,
whicharedividedinturnintoacuteandchronic.Therefore,
leukemia is divided into four categories: acute lympho-
blastic leukemia (ALL), chronic lymphoblastic leukemia
(CLL), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (Gabert et al., 2003).
239 Ecuadorian individuals were analyzed, 137 indi-
viduals with clinical diagnosis of different types of leuke-
mia (ALL = 61, CLL = 1, AML = 15, CML = 60) and 102
healthy individuals with no leukemia diagnosis as a normal
control population. In Ecuador the most important ethnic
groupisknownas“mestizo”(~60%ofthetotalEcuadorian
population), the result of the mixture of Amerindians and
Spaniards (Paz-y-Miño, 1998). The study was approved by
theEthicalCommitteeofthePontificalCatholicUniversity
ofEcuador.Allstudysubjectsreceivedcounselingandpro-
vided written consent for the study.
DNA extraction from bone marrow (leukemia pa-
tients and control population) was performed as described
by (Sambrook et al., 1989). The bone marrow samples ob-
tained from healthy individuals were taken prior to other
medical diagnoses. The hRAD54 gene polymorphism 2290
C/T, in exon 18, was determined by the polymerase chain
reaction - single-strand conformation polymorphism
(PCR-SSCP) method. PCR was performed in a MJ Re-
search PTC-200 thermal cycler (MJ Research, Watertown,
Mass., USA) using primers designed by (Rasio et al.,
1997).Theamplificationreactionwascarriedinafinalvol-
ume of 20 L, containing 1 X reaction buffer, 2.5 mM
MgCl2 (Invitrogen, Carlsbad, CA), 200 M of each dNTP,
2 M of each sense and antisense primers, 1 U of Taq poly-
merase (Invitrogen, Carlsbad, CA) and 100 ng of genomic
DNA as template. PCR conditions consisted of an initial
denaturation at 94 °C for 5 min; followed by 35 cycles of
94°Cfor30s,54°Cfor1min,1min30sat74°C,andafi-
nal extension at 72 °C for 8 min. The amplified fragment of
242 bp was then denatured at 91 °C for 5 min and snap-
cooled for SSCP detection by electrophoresis on a 12%
non-denaturing polyacrylamide (49:1 acrylamide:bisacryl-
amide) gel with 10% of glycerol.
Statistical analyses were done using PASW Statistics
17 for Windows (SPSS, Chicago). Allelic and genotypic
frequencies were also calculated. The non-parametric
Fisher’s exact test was applied to determine significant dif-
ferences between affected (CML = 60, ALL = 61) and
healthy individuals.
The PCR-SSCP method allowed detection of the
three genotypes of the hRAD54 gene polymorphism 2290
C/T (C/C, C/T, T/T) within the studied populations. From
the total 239 individuals analyzed (478 alleles in total), 199
(83.26%) were homozygous for the normal allele (C/C), 38
(15.9%) had a heterozygous genotype (C/T) and two indi-
viduals (0.84%) were homozygous for the polymorphism
(T/T). Of the 42 T alleles present in the studied population,
27 (64.29%) belonged to the study group and 15 (35.71%)
to the control group. In the study group 17 (62.96%) indi-
viduals with CML and 6 (22.22%) individuals with ALL,
presented the T allele (the percentages were calculated
from the base of 27 alleles present in the total study group).
The details of the genotypic distributions and allele fre-
quencies of each group are presented in Table 1. The statis-
tical analysis showed no significant differences between
thecontrolpopulationandthestudygroup(p>0.05).When
we applied the statistical test over the CML and ALL sub-
groups we found differences in the CML subgroup
(p < 0.05), whereas the ALL showed no differences
(p > 0.05).
HR is required to maintain genomic stability and its
absence leads to potentially oncogenic translocations and
other karyotypic changes. While this pathway exists to ef-
fect accurate and “safe” repair, it also has the potential to
misrepairandgeneratedeleteriousproducts.Consequently,
there is strong evolutionary pressure for mechanisms of
apoptosis and cellular senescence which favor eliminating
a cell with chromosomal damage from a dividing popula-
tionovertheriskoferrantrepairandoncogenictransforma-
tion (Ferguson and Frederick, 2001).
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Table 1 - Distribution of the 2290 C/T polymorphism in leukemia (CML,
ALL) and control populations.
Group Genotype Individual
(%)
Genotypic
frequency
Allele
frequency
Leukemia
(n = 137)
C/C 112 (82) 0.82 0.9
C/T 23 (17) 0.17
T/T 2 (1) 0.01 0.1
CML
(n = 60)
C/C 45 (75) 0.75 0.86
C/T 13 (22) 0.22
T/T 2 (3) 0.3 0.14
ALL
(n = 61)
C/C 55 (90) 0.90 0.95
C/T 6 (10) 0.10
T/T 0 (0) 0 0.05
Control
(n = 102)
C/C 87 (85) 0.85 0.925
C/T 15 (15) 0.15
T/T 0 (0) 0 0.075We found Hardy-Weinberg equilibrium in the allele
frequencyofthestudypopulation.Polymorphismsingenes
that are responsible for maintenance of genome stability,
such as hRAD54, could increase the risk to acquire cancer
(Liu et al., 1999; Paz-y-Miño et al., 2003).
When the frequency of the polymorphism in the leu-
kemia group (0.1) was compared with that in the normal
control population (0.1), no statistical difference (p > 0.05)
was observed. However, when we divided the study group
into its two main subgroups, CML and ALL, the calculated
frequencies for the CML subgroup (0.14) showed statisti-
cally significant differences (p < 0.05) from the control
population, whereas those calculates for the ALL subgroup
(0,05) did not. In spite of the results obtained from the sta-
tistical tests, it is important to note that size of the sample is
not large; and that this may pose a limitation for the inter-
pretation of the results.
It has been reported that t(9;22), responsible for some
types of leukemia, especially CML, may be the result of an
aberrant HR process, because the BCR and ABL genes in-
volved in this translocation share some homology in their
sequences(BishopandSchiestl,2002).Thesefindingssug-
gest that the recombinational repair of DSB by HR or spon-
taneous HR are both carried out by the RAD52 epistasis
group (Mazina and Mazin, 2004); among which group the
Rad54 protein plays an especially important role. The 2290
C/TpolymorphismofthehRAD54genecouldbepartofthe
mutator phenotype responsible for the appearance and pro-
gression of malignant transformation (Paz-y-Miño et al.,
2003).However,thismutatorphenotypeseemstobelinked
to CML, but not to other types of leukemia (Sellick et al.,
2008), suggesting that in fact the translocation involved in
CML, t(9;22), is the result of mistakes of the DSB repair
pathwaybyHR,inwhichthehRAD54geneplaysakeyrole
(Bishop and Schiestl, 2002; Symington, 2002).
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